Literature DB >> 11745329

Human Toll-like receptor 2 mediates induction of the antimicrobial peptide human beta-defensin 2 in response to bacterial lipoprotein.

T Birchler1, R Seibl, K Büchner, S Loeliger, R Seger, J P Hossle, A Aguzzi, R P Lauener.   

Abstract

Recognition of pathogens by Drosophila Toll or human Toll-like receptors results in translocation of Dorsal or its human homologue NF-kappaB, respectively; in Drosophila, this is followed by the production of antimicrobial peptides serving as antimicrobial effector system of the innate immune response. We investigated whether human Toll-like receptors also mediate induction of the synthesis of antimicrobial peptides. We found that HEK293 cells transfected with Toll-like receptor 2, but not wild-type cells responded to stimulation with bacterial lipoprotein by production of human beta-defensin 2. Furthermore, the human lung epithelial cell line A549 was found to constitutively express Toll-like receptor 2 and to produce beta-defensin 2 in response to bacterial lipoprotein. This response was abrogated by blocking the signaling pathway activated through Toll-like receptors by transfecting the A549 cells with a dominant-negative form of IRAK-2. Thus, exposure of human cells to bacterial lipoprotein elicits production of the antimicrobial peptide beta-defensin 2 through Toll-like receptor 2.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11745329     DOI: 10.1002/1521-4141(200111)31:11<3131::aid-immu3131>3.0.co;2-g

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  39 in total

Review 1.  Antimicrobial peptides: current status and therapeutic potential.

Authors:  Andreas R Koczulla; Robert Bals
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 2.  Bacterial interactions with cells of the intestinal mucosa: Toll-like receptors and NOD2.

Authors:  E Cario
Journal:  Gut       Date:  2005-04-19       Impact factor: 23.059

3.  Defensins and other antimicrobial peptides at the ocular surface.

Authors:  Alison M McDermott
Journal:  Ocul Surf       Date:  2004-10       Impact factor: 5.033

4.  Expression of functional Toll-like receptors by salivary gland epithelial cells: increased mRNA expression in cells derived from patients with primary Sjögren's syndrome.

Authors:  M P Spachidou; E Bourazopoulou; C I Maratheftis; E K Kapsogeorgou; H M Moutsopoulos; A G Tzioufas; M N Manoussakis
Journal:  Clin Exp Immunol       Date:  2007-03       Impact factor: 4.330

5.  Early bacterial colonization induces toll-like receptor-dependent transforming growth factor beta signaling in the epithelium.

Authors:  Christoph Beisswenger; Elena S Lysenko; Jeffrey N Weiser
Journal:  Infect Immun       Date:  2009-03-02       Impact factor: 3.441

Review 6.  Host defense peptides in wound healing.

Authors:  Lars Steinstraesser; Till Koehler; Frank Jacobsen; Adrien Daigeler; Ole Goertz; Stefan Langer; Marco Kesting; Hans Steinau; Elof Eriksson; Tobias Hirsch
Journal:  Mol Med       Date:  2008 Jul-Aug       Impact factor: 6.354

Review 7.  Toll gates to periodontal host modulation and vaccine therapy.

Authors:  George Hajishengallis
Journal:  Periodontol 2000       Date:  2009       Impact factor: 7.589

Review 8.  Innate immunity in the respiratory epithelium.

Authors:  Dane Parker; Alice Prince
Journal:  Am J Respir Cell Mol Biol       Date:  2011-02-17       Impact factor: 6.914

9.  Suppression of innate immunity by a nasal carriage strain of Staphylococcus aureus increases its colonization on nasal epithelium.

Authors:  Gerry A Quinn; Alexander M Cole
Journal:  Immunology       Date:  2007-04-30       Impact factor: 7.397

10.  MHC class II molecules enhance Toll-like receptor mediated innate immune responses.

Authors:  Remo Frei; Johanna Steinle; Thomas Birchler; Susanne Loeliger; Caroline Roduit; Dirk Steinhoff; Reinhart Seibl; Katja Büchner; Reinhard Seger; Walter Reith; Roger P Lauener
Journal:  PLoS One       Date:  2010-01-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.